
Behind a Museum Door, These Beetles Are Eating Flesh for Science
Deep in the labyrinth of the American Museum of Natural History, past the giant suspended blue whale and the first floor's Alaska brown bears, is an unobtrusive locked door. On it, there is a small sign.
'Bug Colony.'
Behind the door, accessible only to a handful of museum employees, thousands of flesh-eating dermestid beetles toil around the clock handling a task of specimen preparation that even the museum's best trained specialists cannot.
They eat the meat off animal skeletons, leaving only clean bones behind.
Since many skeletons are too fine to be cleaned by human hands, the museum's osteological preparation team turns to the six-legged staffers to prepare them for research and display.
The work is carried out in three gray wooden boxes the size of footlockers that house the colony. They are lined with stainless steel and their flip-up tops reveal beetles swarming the earthly remains of various small animals, mostly birds. They feast upon the gobbets of flesh clinging to the carcasses.
The room is pervaded by the soft, crackling sound of gnawing. 'It sounds like something frying, or Rice Krispies when you add milk,' said Rob Pascocello, the colony's tender.
The beetles are tiny enough — just a few millimeters long — to crawl into the recesses of the smallest animals and nibble away without affecting delicate skeletal structures, said Scott Schaefer, who oversees the museum's collection of more than 30 million specimens and objects.
'They do the fine, detailed work that cannot be done by hand, because it's so delicate,' Mr. Schaefer said. It's gentler than boiling a specimen or soaking it in chemicals or acid.'
Museum officials say the ravenous colony has processed most of the bird collections' more than 30,000 skeleton specimens over the decades, plus countless other forms of carrion. 'They get into the small crevices and, if left unchecked, keep eating until there's nothing left to eat,' Mr. Schaefer said.
On a recent weekday, Paul Sweet, collection manager for the ornithology department, stood in the Bug Room, and in the interest of scientific precision pointed out that its name was imprecise.
True bugs, known to their fans as the Hemiptera order, have mouthparts that pierce and suck. Beetles — Coleoptera — are typically cylindrical and have mouthparts that chew.
The colony had gone to town with those mouthparts to reduce a once-lustrous pink flamingo to a humble bone bundle. A regal snowy owl was similarly picked clean. Then there was the small skeleton in a canister, with bones tinier than toothpicks.
'That's a songbird,' said Mr. Pascocello.
Dermestid beetles are scavengers often found in the wild on animal carcasses, and in the nests, webs and burrows of animals.
Museum officials told The New York Times in 1979 that their dermestid colony had remained self-sustaining since being brought over from Africa in the 1930s. Mr. Sweet said the current group has been around for his entire 35 years at the museum, but could not say for sure if they were the original colony's descendants.
Either way, since a beetle's life is only about six months, 'they're all kissing cousins,' said Mr. Pascocello. He said that while the museum was closed during the coronavirus pandemic, he 'kept a backup colony in my bedroom.'
On this day, Mr. Sweet was looking to skeletonize a northern gannet, a sea bird recovered from Midland Beach on Staten Island. It had been skinned, dried, and trimmed of most of its flesh by researchers before it was handed over to the colony for finishing work.
Within minutes, the carcass was swarmed. The beetles can pick clean a small bird within a couple of days, but may need two weeks for larger skeletons like the gannet.
Mr. Pascocello once served the beetles an orangutan; Mr. Sweet once gave them an emu. But the size of the beetles' boxes is a factor. Larger specimens must be served piecemeal, like the carcass of a feisty Cuban crocodile known as Fidel, obtained from the Bronx Zoo in 2005.
Before the pristine skeletons are boxed and cataloged, they are soaked in water and frozen for days to kill remaining beetles or eggs.
The beetles are not a threat to humans, but an infestation of the museum's specimen collection would be disastrous. Keeping the beetles well fed discourages them from wandering away, as does a strip of Vaseline toward the top of their boxes and a sticky floor section across the room's doorway.
If the supply of specimens should stall, Mr. Pascocello keeps some chicken around as emergency food. Mr. Sweet said he offered the colony pigs' feet during the pandemic because it was the cheapest bone meat at the supermarket.
The gourmandising of the beetles is a reminder that important science is not always conducted in gleaming, hygienic laboratories. On the door, under the 'Bug Colony' sign, is a handwritten addendum:
'Bad odors emanating from behind this door is normal.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
33 minutes ago
- Gizmodo
New Russian Satellite Appears to Be Stalking U.S. Satellite in Orbit
A recently launched Russian satellite is getting uncomfortably cozy with a U.S. reconnaissance satellite, leading Space Command to worry that it's part of an anti-satellite weapon being deployed to orbit. Cosmos 2588 launched on May 23 to a near-circular orbit, placing it eerily close to a U.S. reconnaissance satellite, USA 338. The move prompted suspicion that it's an attempt by Russia to deliberately stalk the U.S. government satellite. This isn't the first time Russia has deployed a sneaky satellite to trail behind and allegedly observe another satellite in orbit, but this time it may be connected to Russia's controversial anti-satellite program. 'U.S. Space Command can confirm Russia's recent launch put a Russian satellite into an orbit near a U.S. government satellite,' a Space Command spokesperson is quoted as saying to Breaking Defense. 'Russia continues to research, develop, test, and deploy a suite of counter space systems that threaten the safety and the stability of the domain, so consistent with all on-orbit objects, USSPACECOM will continue to monitor for concerning behavior or activity related to this launch.' Slingshot Aerospace reports that the alleged spy satellite, Cosmos 2588, is a NIVELIR military inspection satellite likely carrying a kinetic weapon onboard. Its alignment with USA 338 'strongly suggests COSMOS 2588 may be actively monitoring or 'chasing' it,' the satellite tracking company wrote in a statement. Slingshot Aerospace has been tracking the two satellites, revealing that Cosmos 2588 is orbiting at a slightly higher altitude and that the two objects will have a close flyby of one another roughly every four days. The two satellites come as close as 62 miles (100 kilometers) from one another, Marco Langbroek, an astronomer and expert on space situational awareness at the Delft University of Technology in the Netherlands, wrote on X. Not much else is known about USA 338 as it doesn't have publicly available orbital data, but it is believed to be a part of the National Reconnaissance Office's KH-series electro-optical surveillance network, known as the Crystal constellation, according to Interesting Engineering. This isn't the first time Russia has allegedly deployed a satellite for such a purpose. In April 2023, a Russian satellite appeared to be closely trailing a classified U.S. military satellite, and Russia's Kosmos 2558, launched in August 2022, was deployed into the same orbital plane as a U.S. military satellite, dubbed USA 326. In 2020, another Russian satellite, Kosmos 2542, stalked USA 245, an electro-optical spy satellite in low Earth orbit. The U.S. isn't completely innocent either. In June 2017, classified U.S. military satellite USA 276 snuck up on the International Space Station at a close distance of about 4 miles (6.4 kilometers). Earlier in 1998, hobbyists discovered a U.S. satellite that was believed to have been used for space spying purposes as well. Russia's satellites, however, are believed to be part of the country's efforts to develop an anti-satellite weapon designed to destroy other objects in space. In November 2021, Russia destroyed a defunct Soviet-era satellite in low Earth orbit, producing thousands of pieces of orbital debris. The test prompted the United Nations to draft a resolution against tests of anti-satellite (ASAT) missile systems, which was led by the Biden administration after the U.S. adopted a self-imposed ban on ASAT tests. A total of 155 countries voted in favor of the resolution, while nine voted against it, including Russia, China, Cuba, Syria, and Iran. 'This is the fourth time in five years that they launch a satellite into a coplanar orbit with a US optical reconnaissance satellite,' Langbroek wrote on X. 'So no, not mere coincidence but deliberate.'


Medscape
33 minutes ago
- Medscape
Fact or Fiction: Ovarian Cancer and Drug Resistance
In ovarian cancer, the emergence of drug resistance has been shown to limit the durability of therapeutic treatment benefit and contribute substantially to ovarian cancer's high mortality rate. Factors such as treatment-free intervals and tumor microevolution may allow for re-sensitization to platinum agents in select patients. In addition to tumor biology, the tumor microenvironment plays a pivotal role in therapeutic resistance. Targeted therapies, once heralded as a solution to chemotherapy resistance, have been shown to face similar obstacles. Drug resistance in ovarian cancer management is an ongoing field of study as clinicians look to limit its impact improve outcomes. Platinum resistance in ovarian cancer is not always permanent. While many patients relapse with tumors less responsive to platinum-based chemotherapy, resistance can be dynamic. Mechanisms such as epigenetic alterations, modulation of DNA damage response, and temporary activation of drug efflux pumps may contribute to reversible resistance. Importantly, a subset of patients initially labeled as platinum-resistant may benefit from platinum rechallenge after a treatment-free interval, particularly if newer maintenance strategies or resensitizing agents are used. This has led to the concept of a "platinum-free interval" to help guide re-treatment. Understanding these nuances is crucial for tailoring treatment strategies and optimizing outcomes. Learn more about medications used in ovarian cancer. While HRD — often due to BRCA1/2 mutations — initially predicts strong sensitivity to DNA-damaging therapies like platinum agents and PARP inhibitors, resistance commonly emerges over time. A key mechanism is the restoration of homologous recombination through secondary or "reversion" mutations in HR pathway genes. These mutations enable tumor cells to resume high-fidelity DNA repair, diminishing the cytotoxic effects of therapy. Additionally, tumors may activate compensatory pathways such as non-homologous end joining or increase drug efflux activity. This resistance may not be detectable at diagnosis and can evolve under therapeutic pressure. Consequently, current research emphasizes longitudinal molecular monitoring to capture evolving resistance mechanisms. Clinically, this underscores the need for re-biopsy or circulating tumor DNA analysis to reassess HR status in recurrent disease, which may influence therapy selection. Learn more about the importance of biopsy in ovarian cancer. Tumor heterogeneity — both genetic and phenotypic — plays a central role in drug resistance and further complications treatment outcomes. Ovarian tumors often consist of diverse subclonal populations, some of which may possess innate resistance traits. Within a single ovarian tumor, multiple subclonal populations may coexist, each with distinct characteristics and sensitivity profiles. When systemic therapy is applied, sensitive clones are eliminated, but resistant ones may persist and expand. Single-cell and spatial transcriptomics studies have mapped how this clonal evolution occurs, revealing that treatment can select for resistant subpopulations not evident at baseline. Heterogeneity also affects the tumor microenvironment and immune response, further complicating therapeutic strategies. Clinically, this variability can manifest as mixed responses, where some lesions regress while others progress. Addressing heterogeneity remains a major challenge and has sparked interest in combination therapies and adaptive trial designs. Personalized treatment strategies based on real-time tumor profiling are likely to improve outcomes by accounting for this complexity. Learn more about ovarian cancer guidelines. Targeted therapies are susceptible to various resistance mechanisms, many of which overlap with those seen in chemotherapy. For example, resistance to PARP inhibitors, widely used in HRD-positive ovarian cancers, can arise from secondary mutations restoring DNA repair function or through enhanced drug efflux. Similarly, resistance to angiogenesis inhibitors may develop via upregulation of alternative pro-angiogenic pathways or changes in tumor vasculature that circumvent the need for VEGF signaling. Resistance is further complicated by factors such as epigenetic reprogramming and altered cell signaling networks. These findings have led to interest in combining targeted agents with immune checkpoint inhibitors, DNA repair modulators, or epigenetic therapies to overcome resistance. Future success with targeted therapy will likely depend on combination approaches informed by tumor genomics and adaptive resistance profiling. Learn more about risk assessment and genetic counseling in ovarian cancer. The tumor microenvironment (TME) is a key contributor to drug resistance in ovarian cancer. Immune cells such as regulatory T cells and tumor-associated macrophages (TAMs) create an immunosuppressive milieu that hinders effective therapy. Additionally, fibroblasts and extracellular matrix components can form physical barriers that limit drug penetration. Cytokines and growth factors secreted within the TME also modulate signaling pathways in tumor cells, promoting survival and resistance. Studies have shown that high TAM density is associated with poor response to both chemotherapy and immunotherapy, and interventions targeting the TME may help reverse resistance. This includes strategies like macrophage reprogramming, TME remodeling agents, and stromal-targeting therapies. Incorporating TME characteristics into clinical decision-making may help guide therapeutic combinations and predict response. Learn more about tumor biomarkers in ovarian cancer.


The Verge
37 minutes ago
- The Verge
Here's what's inside Meta's experimental new AR glasses
Meta has revealed more information about Aria Gen 2, its experimental smart glasses designed to serve as a test platform for research about augmented reality, AI, and robotics. The glasses pack several improvements into their lightweight frame that could one day translate into consumer products, including an improved eye-tracking system that can track gaze per eye, detect blinks, and estimate the center of pupils. 'These advanced signals enable a deeper understanding of the wearer's visual attention and intentions, unlocking new possibilities for human-computer interaction,' Meta writes. Meta initially announced Aria Gen 2 in February, saying they will 'pave the way for future innovations that will shape the next computing platform.' They build upon Meta's first iteration of the glasses in 2020, which were similarly available for researchers only. Along with an improved eye-tracking system, Aria Gen 2 comes with four computer vision cameras that Meta says enable 3D hand and object tracking. Meta says researchers can use this information to enable highly precise tasks like 'dexterous robot hand manipulation.' The glasses also have a photoplethysmography sensor built into the nosepad, which allows the device to estimate a wearer's heart rate, along with a contact microphone that Meta says provides better audio in loud environments. There's a new ambient light sensor as well, allowing the glasses to differentiate between indoor and outdoor lighting. The Aria Gen 2 glasses include folding arms for the first time, weigh around 75 grams, and come in eight different sizes. Meta plans on opening applications for researchers to work with Aria Gen 2 later this year. The initiative builds on the successful development of Meta's Ray-Ban smart glasses, a form factor it aims to expand with its Orion augmented-reality glasses, a rumored partnership with Oakley, and a high-end pair of 'Hypernova' glasses with a built-in screen.